A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy

In the absence of a proven effective vaccine preventing infection by SARS-CoV-2, or a proven drug to treat COVID-19, the positive results of passive immune therapy using convalescent serum provide a strong lead. We have developed a new class of tetravalent, biparatopic therapy, 89C8-ACE2. It combine...

詳細記述

書誌詳細

主要な著者:	Xiaoniu Miao, Yi Luo, Xi Huang, Suki M. Y. Lee, Zhijun Yuan, Yongzhou Tang, Liandi Chen, Chao Wang, Fan Wu, Yifeng Xu, Wenchao Jiang, Wei Gao, Xuedong Song, Yao Yan, Tuling Pang, Cheng Chen, Yuefeng Zou, Weihui Fu, Liping Wan, Javier Gilbert-Jaramillo, Michael Knight, Tiong Kit Tan, Pramila Rijal, Alain Townsend, Joanne Sun, Xiaolin Liu, William James, Andy Tsun, Yingda Xu
フォーマット:	Artigo
言語:	Inglês
出版事項:	Taylor & Francis Group 2020-01-01
シリーズ:	mAbs
主題:	Biparatopic neutralizing antibody antibody-ACE2 fusion COVID-19 SARS-CoV-2
オンライン･アクセス:	https://www.tandfonline.com/doi/10.1080/19420862.2020.1804241
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!